68043-53-8

Usage

Uses

Used in Pharmaceutical Industry:
6-Nitrochroman-4-one is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be converted into a wide range of biologically active compounds. Its presence in the molecular structure can enhance the pharmacological properties of the resulting drugs, making it an essential component in drug development.
Used in Agricultural Chemicals:
6-Nitrochroman-4-one is used as a precursor in the production of agricultural chemicals, where its chemical properties can be harnessed to create effective pesticides or other agrochemicals that contribute to crop protection and yield enhancement.
Used in Organic Chemistry:
6-Nitrochroman-4-one is used as a versatile building block in organic chemistry for its ability to participate in various chemical reactions, leading to the formation of diverse heterocyclic compounds. Its reactivity and structural features make it a valuable component in the synthesis of complex organic molecules.
Used in Drug Development:
6-Nitrochroman-4-one is used as a starting material in drug development, where its nitro group can be reduced or further modified to create new pharmaceutical agents with potential therapeutic applications. Its significant biological activities make it a promising candidate for the development of novel drugs targeting various diseases and conditions.

InChI:InChI=1/C9H7NO4/c11-8-3-4-14-9-2-1-6(10(12)13)5-7(8)9/h1-2,5H,3-4H2

Upstream product

• 10572-16-4 3-(4-nitrophenoxy)propanoic acid 
• 100-02-7 4-nitro-phenol 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 

Downstream Products

• 51484-05-0 6-nitro-chromen-4-one 
• 82366-90-3 (2-Hydroxy-5-nitro-phenyl)-oxo-acetic acid methyl ester 
• 82366-83-4 3-Methoxy-6-nitro-chroman-4-one 
• 662228-22-0 6-nitrochroman-4-amine 
• 131948-12-4 6-Nitroflavone 
• 1392810-22-8 R/S-N-2-chlorophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2H-1-benzopyran-4-yl)urea 
• 50386-54-4 3,4-dihydro-2H-1-benzopyran-6-amine 
• 178261-85-3 ethyl 6-[(4-cyanobenzoyl)amino]chroman-3-acetate 
• 103441-69-6 6-aminochroman-4-one 

Relevant academic research and scientific papers

Structurally-thrifty and visible-absorbing fluorophores

Fluorophores with a minimal push-pull backbone are actively pursued due to their potentials in biological labelling. Herein a series of structurally-thrifty and visible-absorbing fluorophores (SDXs) were successfully constructed following the D′D-π-A design strategy, in which a secondary donor (D′) was introduced in conjugation with the donor (D) to enhance its electron donating capability. For a very small scaffold, SDXs exhibit a surprisingly long-wavelength absorption band in the visible spectral range (λabs = 420 nm) and a strong green fluorescence emission (λem = 530 nm) with a fluorescence quantum yield up to 0.84. Notably, fluorescence of SDXs was quenched in hydrogen-bonding solvents, e.g. MeOH and H2O. This phenomenon renders SDXs feasibility for imaging of cellular non-hydrogen-bonding microenvironment, as demonstrated with BEAS-2B cells. These results proved that the D′D-π-A is a powerful design strategy to construct novel structurally-thrifty fluorophores.

Anti-tumor drug having multiple kinase inhibition and preparation method and application thereof

The invention discloses an anti-tumor drug having multiple kinase inhibition and a preparation method and application thereof; a compound of formula (I) or its medicinal salt, wherein R1 is hydrogen atom, C1-6 is alkyl, halogenated C1-6 alkyl, halogen, or

Hydrated ferric sulfate-catalyzed reactions of indole with aldehydes, ketones, cyclic ketones, and chromanones: Synthesis of bisindoles and trisindoles

Hydrated ferric sulfate [Fe2(SO4)3·xH2O] has been found to be an efficient catalyst for condensation of bisindoles or trisindoles with aliphatic or aryl aldehydes and ketones including methyl and ethyl-alkyl ketones, methyl aryl ketones, cyclic ketones, and 4-chromanones in 19–96% yields. Trisindoles and 2,2'-alkylidenebisindoles were obtained from indole-3-carbaldehydes or 3-methylindole in 72–84% yields. A total of 43 substrates was employed, giving 33 bisindoles, 3 trisindoles, and one 2:2 product; seventeen of these are new. The best results were obtained from heating ethanolic suspensions, with Fe2(SO4)3·xH2O loaded at 60 mg per mmol of electrophiles. The reaction times were typically 1–4 h, while hindered electrophiles required 8–24 h. These conditions were strong enough to promote 2:1 condensation of indole with substrates without forming higher-order byproducts, with few exceptions. This strategy features tolerance by the catalyst of a wide range of functional groups, readily available starting materials, simple operation, mild reaction conditions, and is environmentally friendly.

ROR-GAMMA MODULATORS AND USES THEREOF

The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by RORγ.

CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS

Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.

C5-SPIRO IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides certain C5-spiro iminothiadiazine dioxide compounds, including compounds Formula (I): or a tautomers and/or stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomers and said stereoisomers, wherein RL, X, Y, R1A, R1B, R2, R3, m, and RA are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS

Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.

Sequential one-pot access to molecular diversity through aniline aqueous borylation

On the basis of our recently reported aniline aqueous borylation, molecular diversity was achieved in a one-pot process by combining other reactions such as esterification, Suzuki-Miyaura coupling, hydrogenolysis, or Petasis borono-Mannich.

Dihydrobenzopyran, thiochroman, tetrahydroquinoleine and tetrahydronaphthalene derivatives and their use in anti-cancer therapy

New dihydrobenzopyran, thiochroman, tetrahydroquinoleine and tetrahydronaphthalene derivatives and their use in anti-cancer therapy with the general formula :

DIHYDROBENZOPYRAN, THIOCHROMAN, TETRAHYDROQUINOLEINE AND TETRAHYDRONAPHTALENE DERIVATIVES AND THEIR USE IN ANTICANCER THERAPY

New dihydrobenzopyran, thiochroman, tetrahydroquinoleine and tetrahydronaphthalene derivatives and their use in anti-cancer therapy with the general formula (I).